SCHEMBL2628202

SCHEMBL2628202

CCCn1cc(C)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934464 0.87 SMPD1 (0.45)
SCHEMBL16526395 0.85 SMPD1 (0.51)
SCHEMBL14289745 0.84 SMPD1 (0.54)
SCHEMBL16263567 0.84 SMPD1 (0.54)
SCHEMBL13469511 0.82 SMPD1 (0.44)
SCHEMBL764212 0.81
SCHEMBL595044 0.80
SCHEMBL255391 0.80
SCHEMBL12386819 0.80
SCHEMBL10065962 0.78 DPP4 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
WO-2024044810-A1 NITRIFICATION INHIBITORS THE UNIVERSITY OF MELBOURNE (AU) 2024-03-07 WO disclosed
WO-2024020164-A2 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. (US) 2024-01-25 WO disclosed
US-20240018583-A1 METHOD FOR ANALYZING HIGHER-ORDER STRUCTURE OF RNA XFOREST THERAPEUTICS CO., LTD. (JP) 2024-01-18 US disclosed
US-11833229-B2 Labeling precursors with squaric acid coupling SCV SPEZIAL-CHEMIKALIEN-VERTRIEBS GMBH (DE) 2023-12-05 US disclosed
WO-2023222762-A1 N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF UNIVERSITY OF ZURICH (CH) 2023-11-23 WO disclosed
EP-4230222-A1 COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-PBD CONJUGATE AND NANOCUPS Oxsonics Limited (GB) 2023-08-23 EP disclosed
US-20230220008-A1 MULTIMERIC BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2023-07-13 US disclosed
US-20220194904-A1 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS CORNELL UNIVERSITY (US) 2022-06-23 US disclosed
WO-2022056273-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. (US) 2022-03-17 WO disclosed
US-20110207767-A1 Novel cc-1065 Analogs and Their Conjugates BYONDIS B.V. (NL) 2011-08-25 US disclosed
US-20100267596-A1 METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS BASE SE (DE) 2010-10-21 US disclosed
EP-2229365-A1 METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS BASF SE (DE) 2010-09-22 EP disclosed
US-20100093720-A1 MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2010-04-15 US disclosed
US-7692030-B2 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer UNIVERSITY OF WASHINGTON (US) 2010-04-06 US disclosed
US-7692030-B2 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer UNIVERSITY OF WASHINGTON (US) 2010-04-06 US disclosed
WO-2009077452-A1 METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS BASF SE (DE) 2009-06-25 WO disclosed
US-20080103192-A1 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER WASHINGTON, UNIVERSITY OF (US) 2008-05-01 US disclosed
US-20080103192-A1 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER WASHINGTON, UNIVERSITY OF (US) 2008-05-01 US disclosed
WO-2008046109-A2 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER UNIVERSITY OF WASHINGTON (US) 2008-04-17 WO disclosed